Cas­sa­va re­sponds to ac­cu­sa­tions of 'sci­en­tif­ic mis­con­duct,' re­it­er­ates sup­port of da­ta be­hind con­tro­ver­sial Alzheimer's drug

Cas­sa­va Sci­ences re­spond­ed in a state­ment Thurs­day to a re­port al­leg­ing mis­con­duct by one of its col­lab­o­ra­tors at the City Uni­ver­si­ty of New York (CUNY), say­ing it stands by the sci­ence be­hind its Phase III Alzheimer’s drug. The re­port­ed find­ings of the in­ves­ti­ga­tion come amid oth­er re­port­ed probes by fed­er­al agen­cies.

Sci­ence re­port­ed Thurs­day that a 50-page re­port from CUNY ac­cused the Cas­sa­va col­lab­o­ra­tor and CUNY fac­ul­ty mem­ber, neu­ro­sci­en­tist Hoau-Yan Wang, of sci­en­tif­ic mis­con­duct in 20 re­search pa­pers, in­clud­ing some that sup­port­ed the ef­fi­ca­cy of its con­tro­ver­sial Alzheimer’s can­di­date simu­fil­am. The CUNY re­port al­so laid blame on Cas­sa­va’s SVP of neu­ro­science and an au­thor on some of the pa­pers, Lind­say Burns.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER